Why did Medline lower its full-year adjusted EBITDA guidance even as it raised its organic sales growth outlook during i

Medline's sales are booming, but its costs are biting with equal force. During its August 5, 2026 results update and conference call [1][3], the company raised its full-year 2026 organic sales growth outlook while cutting its full-year adjusted EBITDA outlook. The guidance moved in opposite directions because the company expects faster sales to come with higher costs, growing pains, and a deliberate choice not to push price increases onto customers [7][89][90].

The setup: strong growth, trimmed profit forecast

• Net sales were up strongly in Q2: about $7.7 billion, a rise of 11.6%, with organic growth near 13% once tariff refund impacts are stripped out [4][31][63].
• Adjusted EBITDA in Q2 grew too, up 13.4% to roughly $1.1 billion [19][35][42].
• Still, Medline raised full-year organic sales guidance to 9%–10%, from 8.5%–9.5%, citing strong demand [18][39][110].
• And at the same time, it lowered full-year adjusted EBITDA guidance to $3.3–$3.4 billion, from $3.5–$3.6 billion [6][22][38][93].

Part of the split is in the math

The organic sales outlook includes tariff-related customer repayments, but the adjusted EBITDA outlook does not include the benefit of tariff refunds [27][28][29][30]. Because of that, the higher sales number and the lower profit number are not measuring exactly the same things.

The size of that one-time benefit matters. Medline said the $243 million net tariff refund benefit was excluded from guidance to reveal true underlying performance, and the underlying Q2 adjusted EBITDA was $817 million [5][92]. In other words, the reported profit was helped by refunds, while the guidance deliberately ignores that help — leaving the underlying cost pressure more visible [21][92].

The costs behind the cut

Medline's official explanation names four main pressures: higher-than-expected inflationary pressure from the Middle East conflict, increased operational investments to support customer demand, quality remediation efforts, and retail channel softness [22][23][26][55]. Digging further into the call materials:

• Middle East conflict inflation: higher fuel and product costs that Medline is absorbing rather than passing on to customers, with about $70 million of impact [7][13][88].
• Operational investments ahead of demand: Medline is adding labor burden three to six months before the related revenue arrives, which weighs on this year's results [14]. The CFO described the company as intentionally "investing in our business for growth ahead of the growth" [90]. These investments create near-term inefficiencies, and about half of the incremental costs from them are expected to be permanent [8].
• Quality remediation: remediation work, including delays in bringing back recalled products such as CHG wipes, is hurting earnings and is expected to continue into 2027 [9].
• Retail channel softness: this weakness was unplanned, is mostly in Medline-branded business, and is Medline-specific — the company lost part of its business at a decent-sized retail customer because its sales team did not understand the customer's needs [16][17].
• Warehouse fire costs: the Tracy, California distribution center fire generated $336 million in costs that were excluded from adjusted EBITDA, with another $50–$100 million expected in the second half, and some of those costs will remain in the base [10]. Fire costs and growth investments were cited as part of the moderated outlook [85][87].
• Tariffs remain a headwind, though a smaller one than feared: the 2026 tariff impact was updated to about $350 million from an original estimate of about $490 million [15].

How big the cut is, and how much is temporary

• The guidance change amounts to about $200 million less at the midpoint [86], with roughly one-third of the incremental costs landing in Q3 and the remaining two-thirds in Q4 [13].
• External factors account for about 25% of the reduction; internal factors such as operational investment, quality remediation, and retail softness account for about 75% [12].
• The CFO estimated that roughly half of the incremental earnings impact is transitory and half is more permanent [11].

The strategic trade-off

Medline is not downplaying the profit pressure. It is choosing it, at least in part. CEO Jim Boyle said it is better to absorb costs and take market share than to take price increases that would later have to be pulled back [89]. So the core reason the guidance split looks contradictory is that the company prefers near-term margin pain in exchange for long-term gain — strong sales today, with the bill for supporting that growth showing up in today's profit outlook [88][89][90].